High-sensitivity detection of autoantibodies against proteinase-3 by a novel third-generation enzyme-linked immunosorbent assay

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 41-46

  Roggenbuck, Dirk ^a   Buettner, Thomas ^a   Hoffmann, Lars ^b   Schmechta, Helmuth ^b   Reinhold, Dirk ^c   Conrad, Karsten ^d  

^a GA GENERIC ASSAYS GMBH   (Germany)

^b Seramun Diagnostica GmbH   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

ANCA; ANCA associated vasculitis; Autoantibody; ELISA; Proteinase 3; Wegener's granulomatosis

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROTEINASE 3 ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; AUTOIMMUNE DISEASE; BLOOD DONOR; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PROTEIN IMMOBILIZATION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SOLID; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 70049091234     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04649.x     Document Type: Conference Paper

References (16)

1. Bosch, X., A. Guilabert, & J. Font. 2006. Antineu-trophil cytoplasmic antibodies. Lancet 368: 404-418.
2. Van der Woude, F.J., et al. 1985. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulo-matosis. Lancet 1: 425-429.
3. Cohen Tervaert, J.W., et al. 1989. Association between active Wegener's granulomatosis and anticy-toplasmic antibodies. Arch. Intern. Med. 149: 2461-2465.
4. Savige, J., W. Pollock & M. Trevisin. 2005. What do antineutrophil cytoplasmic antibodies tell us? Best Pract. Res. Clin. Rheumatol. 19: 263-276.
5. Savige, J., et al. 2003. Addendum to the International Consensus Statement on testing and reporting of anti-neutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune disease. Am. J. Clin. Path. 120: 312-318.
6. Savige J., et al. 1999. International consensus statement on testing and reporting of antineutrophil cyto-plasmic antibodies (ANCA). Am. J. Clin. Pathol. 111: 507-513.
7. Wang, G., et al. 1997. Comparison of eight commercial kits for quantification of antineutrophil cy-toplasmic antibodies (ANCA). J. Immunol. Meth. 208: 203-211.
8. Holle, J.U., et al. 2005. Validations in performance characteristics of commercial enzyme immunoassay kits for the detection of antineutrophil cytoplasmatic antibodies: What is the optimal cut-off? Ann. Rheum. Dis. 64: 1773-1779.
9. Csernok, E., et al. 2004. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies against proteinas-3 in Wegener's granulomatosis: First results from a multicenter study. Rheumatology 43: 174-180.
10. Lee, A.S., et al. 2005. A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in car-boxyterminally tagged recombinant neutrophil serine protease. J. Immunol. Meth. 307: 62-72. Epub 2005 Oct. 3.
11. Hellmich, B., et al. 2007. A novel high sensitive ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. Clin. Exp. Rheumatol. 25(Suppl. 44): S1-S5.
12. Jenette, J., et al. 1994. Nomenclature of systemic vas-culitides. Proposal of an international consensus conference. Arthritis Rheum. 37: 187-192.
13. Hochberg, M.C. 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum. 40: 1725.
14. Hanley, J. & B. McNeil. 1982. The meaning and use of the area under a receiver operating characteristics (ROC) curve. Radiology 143: 29-36.
15. Miller, A., et al. 2008. Assesment of systemic vasculi-tis. Autoimmun. Rev. 8: 170-175.
16. Müller, A., et al. 2007. Human proteinase 3 (PR3) and its binding molecules: implications for inflammatory and PR3-related autoimmune responses. Ann. N. Y. Acad. Sci. 1109: 84-92.